Advice from experienced managers and investors
Ascenion is economically independent. An Advisory Board supports the company on technical and strategic matters.
Manfred Baier, PhD
Dr Manfred Baier has several decades’ experience in the professional development and commercialization of innovative life-science technologies, particularly in the areas of genomics and nanotechnology. He has worked more than 30 years for Roche Diagnostics, most recently as Head of the globally operating business area Roche Applied Science, to which the US genomics companies 454 Life Sciences and NimbleGen belong. He previously held several leadership positions in the concern, including General Manager for Sales, Germany and Head of various business areas. In addition, Dr Manfred Baier is and has been a member of the Board of Directors or Advisory Board of numerous life-science companies, including BioM (D), Heidelberg Innovation (D), TAP Biosystems (UK), Base4Innovation (UK) und Chundsell (S). Dr Baier holds a degree in chemistry and gained his PhD in biochemistry at the University of Stuttgart under the supervision of Professor Pfleiderer.
Timm Jessen, PhD
Since March 2016 Timm Jessen is Chief Executive Officer at Topas Therapeutics GmbH, a spin-off of Evotec AG. Before he worked as Executive Vice President Business Development EVT Innovate at Evotec AG, Managing Director at Bionamics plc, an asset management company and Chief Scientific Officer (CSO) at Evotec AG. Previously he worked for six years in the pharmaceutical industry (Sanofi Aventis) in preclinical research and alliance management. Timm Jessen was trained in chemistry and biochemistry, graduated at the University of Kiel and received his PhD from the University of Munich (Max Planck Institute for Biochemistry).
Joachim Rothe, PhD
Joachim Rothe is responsible for LSP’s German office in Munich and serves or has served on the supervisory boards of Bioxell (I/CH), Affectis (D), U3 Pharma (D), IDEA (D) and Okairos (CH). Before joining LSP as a general partner in early 2002, he was a principal at MPM Capital in Cambridge, MA, USA, and Managing Director of MPM Capital GmbH based in Munich. In that capacity, Joachim served on the supervisory boards of Novirio Pharmaceuticals (now: Nasdaq: IDIX), OMRIX Biopharmaceuticals (now: Nasdaq: OMRI) and t. Breeders (now: Nasdaq: VIAC), and he was significantly involved in the Biovitrum (SSE: BVT) and Cellular Genomics transactions.
Previously, Joachim worked at McKinsey & Company where he was an engagement manager on assignments in the chemical and pharmaceutical industries. He also spent time at Hoffmann-La Roche in Basel, Switzerland, where he worked in both the preclinical development department as well as in central research. Joachim, a German native, has a Masters degree in biochemistry from the Free University in Berlin and a PhD degree from the University of Freiburg. He has authored numerous articles in leading scientific publications, including "Nature".